再生元制药公司(REGN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

REGN 再生元制药公司

交易中 02-27 09:42:10 EST

778.97

+8.18

+1.06%

最高782.00	最低760.91	成交量5.89万
今开760.91	昨收770.79	日振幅2.74%
总市值823.53亿	流通市值804.70亿	总股本1.06亿
成交额4,538万	换手率0.06%	流通股本1.03亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"REGN","market":"US","secType":"STK","nameCN":"再生元制药公司","latestPrice":778.97,"timestamp":1772203325863,"preClose":770.79,"halted":0,"volume":58859,"delay":0,"changeRate":0.010612488485839287,"floatShares":103302739,"shares":105719806,"eps":41.59414,"marketStatus":"交易中","change":8.18,"latestTime":"02-27 09:42:10 EST","open":760.91,"high":782,"low":760.91,"amount":45384883.53354,"amplitude":0.027362,"askPrice":780.85,"askSize":5,"bidPrice":777.53,"bidSize":40,"shortable":3,"etf":0,"ttmEps":41.59414,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1772226000000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":770.79,"dividendRate":0.004519,"preHourTrading":{"tag":"盘前","latestPrice":760.32,"preClose":770.79,"latestTime":"09:29 EST","volume":20542,"amount":15832429.33152,"timestamp":1772202541058,"change":-10.47,"changeRate":-0.013583,"amplitude":0.020421},"postHourTrading":{"tag":"盘后","latestPrice":768,"preClose":770.79,"latestTime":"19:59 EST","volume":29340,"amount":22614695.59,"timestamp":1772153997746,"change":-2.79,"changeRate":-0.00362,"amplitude":0.00362},"volumeRatio":2.69303,"impliedVol":0.3798,"impliedVolPercentile":0.4502},"requestUrl":"/m/hq/s/REGN","defaultTab":"news","newsList":[{"id":"1105620090","title":"再生元制药公司获CHMP建议：扩展Dupixent适用年龄至2-11岁中重度CSU患儿","url":"https://stock-news.laohu8.com/highlight/detail?id=1105620090","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105620090?lang=zh_cn&edition=full","pubTime":"2026-02-27 20:05","pubTimestamp":1772193938,"startTime":"0","endTime":"0","summary":"再生元制药公司近日迎来重要监管进展——欧洲药品管理局人用医药产品委员会已正式建议批准其与赛诺菲联合开发的Dupixent扩大适应症范围，覆盖2至11岁患有中重度慢性自发性荨麻疹的儿童患者群体。若最终获欧盟委员会批准，Dupixent将成为欧洲首个可用于低龄CSU患儿的靶向生物制剂。再生元与赛诺菲计划继续与全球监管机构密切沟通，推动Dupixent在儿科CSU治疗领域的应用拓展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2023250504.SGD","LU0053666078.USD","LU0823434583.USD","BK4588","LU0823434740.USD","LU1974910355.USD","LU0320765992.SGD","LU1917777945.USD","LU0289739699.SGD","LU2362541513.USD","LU0882574055.USD","LU0823416689.USD","LU2089984988.USD","BK4139","LU0109394709.USD","LU0889565916.HKD","LU0114720955.EUR","LU2362541273.HKD","REGN","LU2362540622.SGD","LU0058720904.USD","LU2106854487.HKD","LU2468319806.SGD","BK4585","LU2237438978.USD"],"gpt_icon":0},{"id":"1129492584","title":"欧盟建议批准Dupixent®（度普利尤单抗）用于治疗持续性症状的幼童慢性自发性荨麻疹","url":"https://stock-news.laohu8.com/highlight/detail?id=1129492584","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129492584?lang=zh_cn&edition=full","pubTime":"2026-02-27 20:01","pubTimestamp":1772193690,"startTime":"0","endTime":"0","summary":"再生元制药公司研发的Dupixent®（度普利尤单抗）获得欧盟人用药品委员会积极意见，建议批准用于治疗现有疗法控制不佳的6至11岁慢性自发性荨麻疹患儿。该推荐基于III期临床试验数据，显示度普利尤单抗能显著减轻瘙痒和风团症状。若获欧盟委员会最终批准，这将是首个用于低龄儿童群体的慢性自发性荨麻疹靶向疗法。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0114720955.EUR","LU0289739699.SGD","LU0109394709.USD","REGN","LU0058720904.USD","LU0889565916.HKD","LU0823434740.USD","LU2089984988.USD","BK4585","LU1917777945.USD","LU0823416689.USD","LU2237438978.USD","LU2362541513.USD","BK4139","LU0882574055.USD","LU2362541273.HKD","LU2468319806.SGD","LU2023250504.SGD","LU0823434583.USD","LU2106854487.HKD","LU0320765992.SGD","LU2362540622.SGD","LU0053666078.USD","LU1974910355.USD"],"gpt_icon":0},{"id":"1145911158","title":"欧盟CHMP建议扩大Dupixent（Dupilumab）适用范围：用于治疗2至11岁儿童慢性自发性荨麻疹","url":"https://stock-news.laohu8.com/highlight/detail?id=1145911158","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145911158?lang=zh_cn&edition=full","pubTime":"2026-02-27 18:56","pubTimestamp":1772189798,"startTime":"0","endTime":"0","summary":"欧洲药品管理局人用医药产品委员会（CHMP）近日提出重要建议，支持将Dupixent（dupilumab）的治疗范围扩展至2至11岁儿童群体的慢性自发性荨麻疹。这一突破性进展意味着该药物有望为更广泛的患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823416689.USD","LU2468319806.SGD","LU0320765992.SGD","BK4585","BK4139","LU0889565916.HKD","LU1974910355.USD","LU0823434740.USD","LU2106854487.HKD","REGN","LU2089984988.USD","LU0058720904.USD","LU2237438978.USD","LU2362540622.SGD","LU0109394709.USD","LU2362541513.USD","LU0114720955.EUR","LU2023250504.SGD","LU0289739699.SGD","LU0053666078.USD","LU1917777945.USD","LU0882574055.USD","BK4588","LU0823434583.USD","LU2362541273.HKD"],"gpt_icon":0},{"id":"1153462180","title":"赛诺菲新适应症获批 鼻科疾病版图再拓展：新增过敏性真菌性鼻窦炎 与伴鼻息肉慢性鼻窦炎形成互补","url":"https://stock-news.laohu8.com/highlight/detail?id=1153462180","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153462180?lang=zh_cn&edition=full","pubTime":"2026-02-24 22:35","pubTimestamp":1771943715,"startTime":"0","endTime":"0","summary":"赛诺菲宣布其鼻科疾病治疗领域迎来重要突破——新适应症获得监管批准，使得公司现有治疗范围扩展至过敏性真菌性鼻窦炎（AFRS）。此次获批标志着赛诺菲在鼻科疾病领域的治疗版图实现战略性延伸，与已获批的伴鼻息肉慢性鼻窦炎（CRSwNP）适应症形成协同效应。\n新适应症的纳入不仅丰富了赛诺菲在呼吸道疾病领域的管线布局，更凸显了公司针对复杂鼻科炎症疾病的综合解决方案能力。这一进展将有望为更广泛的患者群体提供新的治疗选择，进一步巩固企业在专科治疗领域的市场地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823434583.USD","BK4588","LU0289739699.SGD","REGN","LU0320765992.SGD","LU0058720904.USD","BK4585","LU0882574055.USD","LU2362541273.HKD","LU2106854487.HKD","LU0889565916.HKD","LU1917777945.USD","LU2023250504.SGD","LU1974910355.USD","LU2468319806.SGD","LU2362540622.SGD","LU0823416689.USD","LU0053666078.USD","LU0114720955.EUR","LU2089984988.USD","LU2237438978.USD","LU0823434740.USD","LU0109394709.USD","LU2362541513.USD","BK4139"],"gpt_icon":0},{"id":"1185973301","title":"再生元制药garetosmab生物制剂许可申请获FDA优先审评资格","url":"https://stock-news.laohu8.com/highlight/detail?id=1185973301","media":"投资观察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185973301?lang=zh_cn&edition=full","pubTime":"2026-02-19 20:18","pubTimestamp":1771503531,"startTime":"0","endTime":"0","summary":"再生元制药公司宣布，其治疗进行性骨化性纤维发育不良（FOP）的药物garetosmab的生物制剂许可申请已获得美国食品药品监督管理局（FDA）的优先审评资格。\nFDA预计将于2026年8月前做出最终审批决定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2362541273.HKD","REGN","LU0058720904.USD","LU2468319806.SGD","BK4585","LU0320765992.SGD","LU0823416689.USD","LU2023250504.SGD","LU1974910355.USD","BK4139","LU0114720955.EUR","LU2089984988.USD","LU0289739699.SGD","LU0823434583.USD","LU2237438978.USD","LU0889565916.HKD","LU0109394709.USD","LU2106854487.HKD","LU1917777945.USD","LU2362541513.USD","LU0882574055.USD","LU0053666078.USD","LU2362540622.SGD","BK4588","LU0823434740.USD"],"gpt_icon":0},{"id":"1139723161","title":"再生元Garetosmab生物制剂许可申请获FDA优先审评资格 用于治疗进行性骨化性纤维发育不良(FOP)","url":"https://stock-news.laohu8.com/highlight/detail?id=1139723161","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139723161?lang=zh_cn&edition=full","pubTime":"2026-02-19 20:01","pubTimestamp":1771502480,"startTime":"0","endTime":"0","summary":"再生元制药公司宣布，其针对进行性骨化性纤维发育不良（FOP）治疗的Garetosmab生物制剂许可申请（BLA）已获美国食品药品监督管理局（FDA）受理，并被授予优先审评资格。这一重要监管进展有望加速该创新疗法的审评进程，为FOP患者带来新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0882574055.USD","LU0114720955.EUR","LU0289739699.SGD","LU2023250504.SGD","LU0889565916.HKD","LU1974910355.USD","LU1917777945.USD","LU2362540622.SGD","LU0823416689.USD","LU2237438978.USD","LU2362541513.USD","LU0320765992.SGD","LU0109394709.USD","BK4588","LU0823434583.USD","LU0053666078.USD","LU0058720904.USD","LU2468319806.SGD","LU2362541273.HKD","LU2106854487.HKD","BK4139","LU0823434740.USD","BK4585","REGN","LU2089984988.USD"],"gpt_icon":0},{"id":"2611197572","title":"再生元制药公司涨2.09% 股价突破800美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2611197572","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611197572?lang=zh_cn&edition=full","pubTime":"2026-02-13 23:36","pubTimestamp":1770996993,"startTime":"0","endTime":"0","summary":"北京时间2026年02月13日23时36分，再生元制药公司股票出现异动，股价大幅拉升2.09%。截至发稿，该股报800.00美元/股，成交量11.9824万股，换手率0.11%，振幅1.90%。机构评级方面，在所有29家参与评级的机构中，72%的券商给予买入建议，28%的券商给予持有建议，无券商给予卖出建议。再生元制药公司股票所在的生物技术行业中，整体涨幅为2.07%。再生元制药公司公司简介：再生元制药发现、开发并商业化对抗眼病、心血管疾病、癌症和炎症的产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021323363497a62230&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021323363497a62230&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0289739699.SGD","LU0823416689.USD","LU2468319806.SGD","LU0823434583.USD","BK4585","LU2023250504.SGD","LU0114720955.EUR","LU0320765992.SGD","LU2362540622.SGD","BK4139","REGN","LU2362541273.HKD","LU0058720904.USD","BK4588","LU2362541513.USD","LU0109394709.USD","LU0882574055.USD","LU0823434740.USD","LU0053666078.USD","LU0889565916.HKD","LU2106854487.HKD","LU2089984988.USD","LU2237438978.USD","LU1917777945.USD","LU1974910355.USD"],"gpt_icon":0},{"id":"2610621562","title":"再生元制药公司在AAAAI年会上展示了其免疫学管道的最新进展Regeneron Pharmaceuticals Presents Updates on Immunology Pipeline at AAAAI Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2610621562","media":"动脉网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610621562?lang=zh_cn&edition=full","pubTime":"2026-02-10 21:09","pubTimestamp":1770728940,"startTime":"0","endTime":"0","summary":"During the presentation, Regeneron highlighted progress across multiple investigational therapies targeting allergic and inflammatory conditions. These included updates on clinical trials evaluating potential treatments for chronic spontaneous urticaria, food allergies, and other immune-related disorders.在演讲中，Regeneron 强调了其在针对过敏和炎症性疾病的多项研究性疗法中取得的进展。The company also discussed ongoing research into monoclonal antibodies designed to modulate specific pathways involved in allergic responses. Additionally, Regeneron shared data from studies exploring innovative therapeutic strategies to address unmet needs in allergy treatment..该公司还讨论了正在进行的单克隆抗体研究，这些抗体旨在调节与过敏反应相关的特定通路。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210211130a493c179&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210211130a493c179&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1974910355.USD","LU2106854487.HKD","BK4585","LU2362541513.USD","LU2089984988.USD","LU0053666078.USD","LU0823434583.USD","LU0289739699.SGD","LU2362541273.HKD","LU0889565916.HKD","LU2468319806.SGD","LU2237438978.USD","REGN","BK4139","LU0320765992.SGD","LU0882574055.USD","LU1917777945.USD","LU2362540622.SGD","LU0823434740.USD","LU0109394709.USD","LU0058720904.USD","LU2023250504.SGD","BK4588","LU0114720955.EUR","LU0823416689.USD"],"gpt_icon":0},{"id":"1109277950","title":"再生元Eylea Hd®（阿柏西普）8毫克注射液亮相Angiogenesis 2026，凸显其治疗严重视网膜疾病的强劲临床实力","url":"https://stock-news.laohu8.com/highlight/detail?id=1109277950","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109277950?lang=zh_cn&edition=full","pubTime":"2026-02-02 20:02","pubTimestamp":1770033744,"startTime":"0","endTime":"0","summary":"在近日举行的Angiogenesis 2026大会上，再生元制药公司重磅公布了其Eylea Hd8毫克注射液的最新临床数据。这些详实的报告进一步巩固了该疗法在应对严重视网膜疾病领域的卓越临床地位。多项研究结果集中展示，凸显了Eylea Hd在延长给药间隔、提升患者依从性方面的显著优势，同时其安全性与耐受性特征与已知信息保持一致。此次亮相强化了Eylea Hd作为严重视网膜疾病治疗基石的角色，彰显了再生元在眼科创新疗法研发上的持续投入与领先优势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2362541273.HKD","LU0823434740.USD","REGN","LU2106854487.HKD","LU0053666078.USD","BK4585","LU1974910355.USD","LU2362540622.SGD","BK4139","LU0320765992.SGD","LU2089984988.USD","LU0823416689.USD","LU2362541513.USD","LU0882574055.USD","LU0823434583.USD","LU1917777945.USD","LU2468319806.SGD","LU2237438978.USD","LU0058720904.USD","LU0114720955.EUR","BK4588","LU0109394709.USD","LU0889565916.HKD","LU2023250504.SGD","LU0289739699.SGD"],"gpt_icon":0},{"id":"1107020252","title":"再生元制药高管称正积极与美国机构进行建设性对话，预期达成符合既有企业框架的协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1107020252","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107020252?lang=zh_cn&edition=full","pubTime":"2026-01-30 21:44","pubTimestamp":1769780651,"startTime":"0","endTime":"0","summary":"再生元制药公司高管在电话会议中表示，公司正积极与美国相关机构展开建设性讨论，并预期最终能达成一项符合其他企业先前所确立框架的协议。这一进展标志着公司在合规与协作方面迈出重要步伐，有望为未来业务运营奠定稳固基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2106854487.HKD","LU0823416689.USD","LU0114720955.EUR","LU0882574055.USD","LU1974910355.USD","BK4588","LU0823434740.USD","LU2468319806.SGD","LU0058720904.USD","LU2023250504.SGD","LU0109394709.USD","LU0053666078.USD","LU1917777945.USD","BK4585","LU2362541273.HKD","LU2362540622.SGD","BK4139","LU0823434583.USD","LU0289739699.SGD","LU0889565916.HKD","LU2362541513.USD","LU2089984988.USD","LU0320765992.SGD","LU2237438978.USD","REGN"],"gpt_icon":0},{"id":"1142288398","title":"再生元高管透露：Catalent持续与美国FDA协作解决先前调查发现的问题","url":"https://stock-news.laohu8.com/highlight/detail?id=1142288398","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142288398?lang=zh_cn&edition=full","pubTime":"2026-01-30 21:40","pubTimestamp":1769780418,"startTime":"0","endTime":"0","summary":"再生元制药公司高管在电话会议中表示，其合作伙伴Catalent公司正持续与美国食品药品监督管理局积极协作，致力于解决此前调查中发现的相关问题。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0114720955.EUR","LU1974910355.USD","LU0320765992.SGD","LU2023250504.SGD","LU0889565916.HKD","LU0823434583.USD","REGN","LU2106854487.HKD","LU2468319806.SGD","LU0053666078.USD","BK4588","LU2362540622.SGD","LU0823434740.USD","LU0058720904.USD","LU2237438978.USD","LU1917777945.USD","LU0289739699.SGD","LU0882574055.USD","LU2362541513.USD","LU2362541273.HKD","LU0823416689.USD","LU0109394709.USD","BK4585","BK4139","LU2089984988.USD"],"gpt_icon":0},{"id":"1197765938","title":"再生元高管表示低剂量Eylea将面临竞争压力，预计2026年下半年加剧——电话会议","url":"https://stock-news.laohu8.com/highlight/detail?id=1197765938","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197765938?lang=zh_cn&edition=full","pubTime":"2026-01-30 21:40","pubTimestamp":1769780417,"startTime":"0","endTime":"0","summary":"再生元制药公司高管在电话会议中指出，其产品低剂量Eylea预计将面临市场竞争压力，且这一压力可能在2026年下半年进一步加剧。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053666078.USD","REGN","LU2237438978.USD","LU0114720955.EUR","LU0889565916.HKD","LU2362541513.USD","BK4588","LU1974910355.USD","LU0320765992.SGD","LU1917777945.USD","LU0823434583.USD","BK4139","LU2106854487.HKD","LU2023250504.SGD","LU0823416689.USD","LU0823434740.USD","LU0289739699.SGD","LU2362540622.SGD","LU0058720904.USD","LU2362541273.HKD","LU0882574055.USD","BK4585","LU0109394709.USD","LU2468319806.SGD","LU2089984988.USD"],"gpt_icon":0},{"id":"1115541760","title":"财报前瞻｜再生元制药公司本季度营收预计小幅增长，机构观点偏谨慎","url":"https://stock-news.laohu8.com/highlight/detail?id=1115541760","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115541760?lang=zh_cn&edition=full","pubTime":"2026-01-23 10:04","pubTimestamp":1769133873,"startTime":"0","endTime":"0","summary":"再生元制药公司将在2026年01月30日发布最新季度财报，市场普遍预期营收与利润边际承压，但核心产品与合作收入结构稳健，关注本季度指引与新产品推进节奏。根据工具数据，本季度总收入预计为37.69亿美元，同比增长0.52%；调整后每股收益预计为10.71美元，同比下降5.01%；EBIT预计为12.06亿美元，同比下降13.37%。上季度公司披露的对本季度的具体毛利率、净利润或净利率预测未在可用信息中查询到。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"财报前瞻｜再生元制药公司本季度营收预计小幅增长，机构观点偏谨慎","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"gpt_icon":0},{"id":"2603685535","title":"再生元制药公司涨0.27% 股价突破800美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2603685535","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603685535?lang=zh_cn&edition=full","pubTime":"2026-01-12 22:31","pubTimestamp":1768228293,"startTime":"0","endTime":"0","summary":"北京时间2026年01月12日22时31分，再生元制药公司股票出现波动，股价急速上涨0.27%。截至发稿，该股报798.72美元/股，成交量4.3729万股，换手率0.04%，振幅1.95%。机构评级方面，在所有30家参与评级的机构中，70%的券商给予买入建议，30%的券商给予持有建议，无券商给予卖出建议。再生元制药公司股票所在的生物技术行业中，整体跌幅为0.64%。再生元制药公司公司简介：再生元制药发现、开发并商业化对抗眼病、心血管疾病、癌症和炎症的产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112223134a4bb0ea1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112223134a4bb0ea1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0053666078.USD","LU0109394709.USD","LU0289739699.SGD","LU2023250504.SGD","LU2362541273.HKD","LU0823434740.USD","LU0058720904.USD","LU0882574055.USD","LU2089984988.USD","LU0889565916.HKD","LU2362541513.USD","BK4585","LU0823416689.USD","LU2237438978.USD","LU2362540622.SGD","LU1917777945.USD","LU0114720955.EUR","LU0823434583.USD","BK4139","LU1974910355.USD","LU0320765992.SGD","LU2468319806.SGD","LU2106854487.HKD","BK4588","REGN"],"gpt_icon":0},{"id":"1183550675","title":"再生元制药公司：IPR&D费用将导致2025年第四季度调整后每股收益减少0.14美元——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1183550675","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183550675?lang=zh_cn&edition=full","pubTime":"2026-01-12 19:51","pubTimestamp":1768218682,"startTime":"0","endTime":"0","summary":"根据最新提交的美国证券交易委员会（SEC）文件显示，再生元制药公司确认，一项与IPR&D（进程中的研发项目）相关的费用，预计将对2025年第四季度的调整后每股收益产生负面影响，具体减少金额为0.14美元。\n这一费用反映了公司在研发领域的持续投入与战略调整。尽管短期内会对盈利指标造成压力，但它也凸显了再生元制药长期致力于创新药物开发的决心。投资者在评估公司未来业绩时，需综合考虑此类战略性支出对长期价值创造的潜在贡献。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0114720955.EUR","LU2023250504.SGD","LU2237438978.USD","LU1917777945.USD","LU0053666078.USD","LU2362540622.SGD","BK4588","LU0889565916.HKD","BK4139","LU0320765992.SGD","LU0289739699.SGD","LU0058720904.USD","LU2362541513.USD","LU2468319806.SGD","LU2106854487.HKD","LU0109394709.USD","LU0823434583.USD","REGN","LU2089984988.USD","LU2362541273.HKD","LU0882574055.USD","LU1974910355.USD","BK4585","LU0823416689.USD","LU0823434740.USD"],"gpt_icon":0},{"id":"2602450584","title":"再生元制药公司跌0.13% 股价跌破800美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2602450584","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602450584?lang=zh_cn&edition=full","pubTime":"2026-01-10 00:36","pubTimestamp":1767976611,"startTime":"0","endTime":"0","summary":"北京时间2026年01月10日00时36分，再生元制药公司股票出现波动，股价快速跳水0.13%。截至发稿，该股报800.00美元/股，成交量25.4784万股，换手率0.24%，振幅2.62%。最近的财报数据显示，该股实现营业收入37.54亿美元，净利润14.60亿美元，每股收益14.09美元，毛利30.96亿美元，市盈率19.18倍。再生元制药公司股票所在的生物技术行业中，整体涨幅为0.75%。再生元制药公司公司简介：再生元制药发现、开发并商业化对抗眼病、心血管疾病、癌症和炎症的产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260110003651a7081e1c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260110003651a7081e1c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0053666078.USD","LU0058720904.USD","LU0823434583.USD","LU0889565916.HKD","LU1917777945.USD","LU2362540622.SGD","LU2362541273.HKD","LU1974910355.USD","LU0882574055.USD","LU0320765992.SGD","BK4139","LU2362541513.USD","LU0823434740.USD","LU2237438978.USD","LU0109394709.USD","LU0114720955.EUR","LU2468319806.SGD","BK4585","LU0823416689.USD","LU2089984988.USD","REGN","BK4588","LU2023250504.SGD","LU2106854487.HKD","LU0289739699.SGD"],"gpt_icon":0},{"id":"1103404064","title":"再生元制药公司获美银全球研究上调评级至“买入” 盘前股价应声上涨2.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1103404064","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103404064?lang=zh_cn&edition=full","pubTime":"2026-01-07 19:37","pubTimestamp":1767785828,"startTime":"0","endTime":"0","summary":"在美银全球研究将其股票评级从“跑输大盘”上调至“买入”后，再生元制药公司（Regeneron Pharmaceuticals）股价在盘前交易时段应声走高，涨幅达2.3%。\n此次评级上调反映了市场对该公司前景的积极预期转变，并直接提振了投资者信心，推动其股价在开盘前显著上扬。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053666078.USD","LU0889565916.HKD","LU0109394709.USD","BK4585","LU0320765992.SGD","LU2089984988.USD","LU2362541513.USD","LU0823434740.USD","LU0823416689.USD","LU0882574055.USD","LU2362540622.SGD","LU0114720955.EUR","LU2023250504.SGD","LU1974910355.USD","LU2362541273.HKD","REGN","LU0289739699.SGD","LU2106854487.HKD","LU1917777945.USD","LU0058720904.USD","LU0823434583.USD","LU2237438978.USD","BK4588","BK4139","LU2468319806.SGD"],"gpt_icon":0},{"id":"1187319297","title":"美银全球研究上调再生元制药评级至买入 目标价跃升至860美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1187319297","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187319297?lang=zh_cn&edition=full","pubTime":"2026-01-07 19:27","pubTimestamp":1767785239,"startTime":"0","endTime":"0","summary":"美银全球研究（Bofa Global Research）发布最新报告，将再生元制药公司的投资评级从\"表现不佳\"大幅上调至\"买入\"级别。与此同时，该机构将其目标股价从每股627美元显著提升至860美元，显示出对该公司未来业绩的强劲信心。\n此次评级调整反映了分析师对再生元制药核心业务增长潜力的重新评估。目标价的大幅上调表明，美银全球研究认为该公司在医药研发领域的领先地位，以及其创新药物管线的商业价值尚未被市场充分定价。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0882574055.USD","LU0114720955.EUR","LU0289739699.SGD","LU2023250504.SGD","LU0889565916.HKD","LU1974910355.USD","LU1917777945.USD","LU2362540622.SGD","LU0823416689.USD","LU2237438978.USD","LU2362541513.USD","LU0320765992.SGD","LU0109394709.USD","BK4588","LU0823434583.USD","LU0053666078.USD","LU0058720904.USD","LU2468319806.SGD","LU2362541273.HKD","LU2106854487.HKD","BK4139","LU0823434740.USD","BK4585","REGN","LU2089984988.USD"],"gpt_icon":0},{"id":"1165078073","title":"新闻发布：赛诺菲与再生元制药公司的Dupixent在日本获得批准，用于6至11岁支气管哮喘儿童的治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1165078073","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165078073?lang=zh_cn&edition=full","pubTime":"2025-12-23 14:06","pubTimestamp":1766469989,"startTime":"0","endTime":"0","summary":"新闻发布：赛诺菲与再生元制药公司的Dupixent在日本获得批准，用于6至11岁支气管哮喘儿童的治疗","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823434583.USD","LU0823416689.USD","LU0823434740.USD","LU0058720904.USD","BK4585","BK4588","LU2362541273.HKD","REGN","LU1917777945.USD","LU1974910355.USD","LU0320765992.SGD","LU2089984988.USD","LU2106854487.HKD","LU0289739699.SGD","LU2237438978.USD","LU0053666078.USD","LU0889565916.HKD","LU2362541513.USD","LU2023250504.SGD","LU0114720955.EUR","LU2468319806.SGD","LU0109394709.USD","LU0882574055.USD","BK4139","LU2362540622.SGD"],"gpt_icon":0},{"id":"2592139231","title":"默沙东(MRK.US)、施贵宝(BMY.US)等多家药企同意下调美国药价 以换取特朗普政府关税豁免和政策支持","url":"https://stock-news.laohu8.com/highlight/detail?id=2592139231","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592139231?lang=zh_cn&edition=full","pubTime":"2025-12-20 07:00","pubTimestamp":1766185200,"startTime":"0","endTime":"0","summary":"美国总统特朗普推动将美国药价与海外低价市场挂钩之际，多家美国及欧洲大型制药企业近日与白宫达成协议，同意自愿下调在美销售的药品价格，以换取关税豁免和政策支持。在此次协议中，最受市场关注的是施贵宝的让利承诺。特朗普在周五的公开活动上表示，今年7月他致信要求降价的17家大型制药企业中，已有14家同意大幅下调药价。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"2acbaf8fbf691a451fa9ea170ee88816","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384042.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1066051811.HKD","LU1868837136.USD","LU0266013472.USD","LU1116320901.HKD","LU0289739699.SGD","LU1868836757.USD","LU0130517989.USD","LU1037948897.HKD","MRK","SG9999015341.SGD","LU1983299246.USD","LU0237698245.USD","LU0965509010.AUD","LU0306806265.USD","LU1201861249.SGD","LU1868836914.USD","LU1699723380.USD","LU1291159041.SGD","SG9999001440.SGD","IE00B4R5TH58.HKD","IE00BLSP4239.USD","LU1670711040.USD","LU0238689110.USD","LU0070302665.USD","LU0456855351.SGD","LU0225284248.USD","LU1934455863.HKD","LU0096364046.USD","LU2361045086.USD","LU2242652126.USD","BK4533","IE00BLSP4452.SGD","LU1989772840.SGD","LU1057294990.SGD","LU1989771016.USD","LU1670710661.SGD","LU1032466523.USD","SG9999001176.SGD","LU1974910355.USD","SG9999013999.USD","SNY","LU2360032135.SGD","IE00BFTCPJ56.SGD","LU0320765489.SGD","IE0009355771.USD","LU2361044865.SGD","LU0098860793.USD","LU0265550946.USD","LU0114720955.EUR","IE00BFXG1179.USD","LU0321505439.SGD","LU1430594728.SGD","LU0306807586.USD","LU1162221912.USD","LU1323610961.USD","LU0006306889.USD","NVS","LU2361044949.HKD","LU1066053197.SGD","LU1116320737.USD","LU2125154935.USD","LU1035773651.USD","GSK","BK4559","LU0882574055.USD","LU1718418525.SGD","LU1868837300.USD","LU0320765646.SGD","LU2106854487.HKD","LU2089984988.USD","IE00B2B36J28.USD","LU0868494617.USD","LU1941712348.USD","IE00BSNM7G36.USD","IE00B1BXHZ80.USD","LU0106261372.USD","LU0265550359.USD","LU2023250843.SGD","LU1585245621.USD","SG9999014567.USD","SG9999014575.USD","LU0267386448.USD","BK4532","BK4585","LU2461242641.AUD","LU2023250504.SGD","LU2112291526.USD","LU1061106388.HKD","LU0980610538.SGD","LU1989772923.USD","ABBV","LU2242646821.SGD","SG9999002232.USD","LU0965508806.USD","LU1066051225.USD","BK4534","04332","IE00BBT3K403.USD","SGXZ57979304.SGD","REGN","SG9999014559.SGD","BK4588","LU1670710588.SGD","IE0002141913.USD","IE00BN8TJ469.HKD","SG9999001176.USD","GILD","IE000M9KFDE8.USD","LU0203347892.USD","LU0985320562.USD","LU0130102774.USD","LU1929549753.HKD","ROG","LU1037948541.HKD","LU1868836591.USD","SG9999015358.SGD","AMGN","BK4516","LU0965509283.SGD","LU1670711123.USD","LU0985481810.HKD","BK4550","LU1934455277.USD","LU1023059063.AUD","LU0203345920.USD","LU2468319806.SGD","LU1571399168.USD","LU1093756325.SGD","LU1934455194.USD","BK4581","LU0477156953.USD","LU0225771236.USD","LU1093756168.USD","LU0122379950.USD","LU1066051498.USD","BMY","LU2125154778.USD","LU0965509101.SGD","LU0861579265.USD","LU1261432733.SGD","LU1941712264.USD","SG9999014542.SGD","LU0058720904.USD","LU0648001328.SGD","LU0321505868.SGD","SG9999002224.SGD","AZN","BK4007","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","LU2324357040.USD","LU1069347547.HKD","LU0211331839.USD","LU2133065610.SGD","LU1917777945.USD","LU0234572021.USD","LU0061475181.USD","LU1074936037.SGD","JNJ","LU0208291251.USD"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.regeneron.com","stockEarnings":[{"period":"1week","weight":-0.0148},{"period":"1month","weight":-0.0006},{"period":"3month","weight":-0.012},{"period":"6month","weight":0.3273},{"period":"1year","weight":0.0903},{"period":"ytd","weight":-0.0014}],"compareEarnings":[{"period":"1week","weight":0.007},{"period":"1month","weight":-0.0089},{"period":"3month","weight":0.0086},{"period":"6month","weight":0.0686},{"period":"1year","weight":0.1594},{"period":"ytd","weight":0.0108}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"再生元制药公司于1988年在纽约州注册成立。该公司是一家完全整合的生物技术公司，为患有严重疾病的人发明、开发、制造和商业化药物。其核心业务战略建立在科研和专有技术的强大基础之上，推进跨多个治疗领域的多样化产品和候选产品组合。","yearOnYearQuotes":[{"month":1,"riseRate":0.514286,"avgChangeRate":0.03675},{"month":2,"riseRate":0.428571,"avgChangeRate":0.086436},{"month":3,"riseRate":0.470588,"avgChangeRate":-0.044318},{"month":4,"riseRate":0.470588,"avgChangeRate":0.017191},{"month":5,"riseRate":0.628571,"avgChangeRate":0.057479},{"month":6,"riseRate":0.428571,"avgChangeRate":0.006745},{"month":7,"riseRate":0.657143,"avgChangeRate":0.052646},{"month":8,"riseRate":0.542857,"avgChangeRate":0.022877},{"month":9,"riseRate":0.457143,"avgChangeRate":0.023281},{"month":10,"riseRate":0.4,"avgChangeRate":-0.00141},{"month":11,"riseRate":0.542857,"avgChangeRate":0.046018},{"month":12,"riseRate":0.485714,"avgChangeRate":0.043803}],"exchange":"NASDAQ","name":"再生元制药公司","nameEN":"Regeneron Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"再生元制药公司(REGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供再生元制药公司(REGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"再生元制药公司,REGN,再生元制药公司股票,再生元制药公司股票老虎,再生元制药公司股票老虎国际,再生元制药公司行情,再生元制药公司股票行情,再生元制药公司股价,再生元制药公司股市,再生元制药公司股票价格,再生元制药公司股票交易,再生元制药公司股票购买,再生元制药公司股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"再生元制药公司(REGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供再生元制药公司(REGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}